Eisai launches Lenvima in China

The Chinese subsidiary of Japan’s Eisai (TYO: 4523) has launched the kinase inhibitor Lenvima (lenvatinib mesylate) in China.

In China, Lenvima was approved first as a single agent for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy in September 2018. Through this launch, Lenvima is the first new systemic therapy in around 10 years available for the first-line treatment of unresectable HCC in China, where the incidence of HCC is the highest in the world, noted Eisai, whose shares were up 1.07% at 10,350 yen.